The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Conversation with The Cancer Letter

As his center wins comprehensive (again), Carlos Arteaga tells us how NCI’s standards have evolved

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

NCI has renewed the Harold C. Simmons Comprehensive Cancer Center’s comprehensive designation.

“I think this is special, because I think it is a marker of an evolution of the institution, which has always been a basic science powerhouse, and now is enhancing an increasingly outstanding enterprise in translational cancer research and cancer care, community outreach and engagement, and education and training in cancer,” Carlos L. Arteaga, director of the Simmons Cancer Center at UT Southwestern, said to The Cancer Letter.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account